Pontine Glioma - Pipeline Review, H1 2018

  • ID: 4540578
  • Report
  • 257 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • AbbVie Inc
  • AstraZeneca Plc
  • Celgene Corp
  • Loxo Oncology Inc
  • NewLink Genetics Corp
  • Pfizer Inc
  • MORE
Pontine Glioma - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Pontine Glioma - Pipeline Review, H1 2018, provides an overview of the Pontine Glioma (Oncology) pipeline landscape.

Pontine glioma are highly aggressive and difficult to treat brain tumors found at the base of the brain. One of the most common types is diffuse intrinsic pontine glioma (DIPG). DIPG affects the pons portion of the brainstem, rendering nervous system function impossible. Symptoms include double vision, inability to close the eyelids completely, dropping one side of the face, and difficulty chewing and swallowing.

Report Highlights:

This latest pipeline guide Pontine Glioma - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Pontine Glioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pontine Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pontine Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 12, 8, 7, 1 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 3 and 1 molecules, respectively.

Pontine Glioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pontine Glioma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Pontine Glioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pontine Glioma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pontine Glioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pontine Glioma (Oncology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pontine Glioma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pontine Glioma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc
  • AstraZeneca Plc
  • Celgene Corp
  • Loxo Oncology Inc
  • NewLink Genetics Corp
  • Pfizer Inc
  • MORE
Introduction

Pontine Glioma - Overview

Pontine Glioma - Therapeutics Development

Pontine Glioma - Therapeutics Assessment

Pontine Glioma - Companies Involved in Therapeutics Development

Pontine Glioma - Drug Profiles

Pontine Glioma - Dormant Projects

Pontine Glioma - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Pontine Glioma, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pontine Glioma - Pipeline by AbbVie Inc, H1 2018

Pontine Glioma - Pipeline by Apexigen Inc, H1 2018

Pontine Glioma - Pipeline by Arog Pharmaceuticals Inc, H1 2018

Pontine Glioma - Pipeline by AstraZeneca Plc, H1 2018

Pontine Glioma - Pipeline by Boehringer Ingelheim GmbH, H1 2018

Pontine Glioma - Pipeline by Bristol-Myers Squibb Co, H1 2018

Pontine Glioma - Pipeline by Burzynski Research Institute Inc, H1 2018

Pontine Glioma - Pipeline by Celgene Corp, H1 2018

Pontine Glioma - Pipeline by DNAtrix Inc, H1 2018

Pontine Glioma - Pipeline by Insys Therapeutics Inc, H1 2018

Pontine Glioma - Pipeline by Loxo Oncology Inc, H1 2018

Pontine Glioma - Pipeline by Medicenna Therapeutics Corp, H1 2018

Pontine Glioma - Pipeline by Midatech Pharma Plc, H1 2018

Pontine Glioma - Pipeline by Moleculin Biotech Inc, H1 2018

Pontine Glioma - Pipeline by NewLink Genetics Corp, H1 2018

Pontine Glioma - Pipeline by Novartis AG, H1 2018

Pontine Glioma - Pipeline by Ono Pharmaceutical Co Ltd, H1 2018

Pontine Glioma - Pipeline by Pfizer Inc, H1 2018

Pontine Glioma - Pipeline by PTC Therapeutics Inc, H1 2018

Pontine Glioma - Pipeline by Sanofi, H1 2018

Pontine Glioma - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2018

Pontine Glioma - Pipeline by ZIOPHARM Oncology Inc, H1 2018

Pontine Glioma - Dormant Projects, H1 2018

List of Figures

Number of Products under Development for Pontine Glioma, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AbbVie Inc
  • Apexigen Inc
  • Arog Pharmaceuticals Inc
  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co
  • Burzynski Research Institute Inc
  • Celgene Corp
  • DNAtrix Inc
  • Insys Therapeutics Inc
  • Loxo Oncology Inc
  • Medicenna Therapeutics Corp
  • Midatech Pharma Plc
  • Moleculin Biotech Inc
  • NewLink Genetics Corp
  • Novartis AG
  • Ono Pharmaceutical Co Ltd
  • Pfizer Inc
  • PTC Therapeutics Inc
  • Sanofi
  • Sumitomo Dainippon Pharma Co Ltd
  • ZIOPHARM Oncology Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll